

ALDH1/2 (H-8): sc-166362

BACKGROUND

Aldehyde dehydrogenases (ALDHs) mediate NADP⁺-dependent oxidation of aldehydes into acids during the detoxification of alcohol-derived acetaldehyde; metabolism of corticosteroids, biogenic amines and neurotransmitters; and lipid peroxidation. ALDH1A1, also designated retinal dehydrogenase 1 (RALDH1 or RALDH1), aldehyde dehydrogenase family 1 member A1, aldehyde dehydrogenase cytosolic, ALDH1L1, ALDH-E1 or ALDH E1, is a retinal dehydrogenase that participates in the biosynthesis of retinoic acid (RA). The major liver isoform ALDH1 localizes to cytosolic space, while ALDH2 localizes to the mitochondria. The ALDH1A2 (RALDH2, RALDH2-T) gene produces three different transcripts and also catalyzes the synthesis of RA from retinaldehyde. ALDH2 is present in most Caucasians, yet is absent in 50% of Asians. The absence of this enzyme has been linked to alcohol intolerance and, thusly, a reduced risk for alcoholism-related liver disease.

SOURCE

ALDH1/2 (H-8) is a mouse monoclonal antibody raised against amino acids 186-270 mapping within an internal region of ALDH1A1 of human origin.

PRODUCT

Each vial contains 200 µg IgG_{2b} kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

ALDH1/2 (H-8) is available conjugated to agarose (sc-166362 AC), 500 µg/0.25 ml agarose in 1 ml, for IP; to HRP (sc-166362 HRP), 200 µg/ml, for WB, IHC(P) and ELISA; to either phycoerythrin (sc-166362 PE), fluorescein (sc-166362 FITC), Alexa Fluor® 488 (sc-166362 AF488), Alexa Fluor® 546 (sc-166362 AF546), Alexa Fluor® 594 (sc-166362 AF594) or Alexa Fluor® 647 (sc-166362 AF647), 200 µg/ml, for WB (RGB), IF, IHC(P) and FCM; and to either Alexa Fluor® 680 (sc-166362 AF680) or Alexa Fluor® 790 (sc-166362 AF790), 200 µg/ml, for Near-Infrared (NIR) WB, IF and FCM.

Alexa Fluor® is a trademark of Molecular Probes, Inc., Oregon, USA

APPLICATIONS

ALDH1/2 (H-8) is recommended for detection of ALDH1A1, ALDH1A2, ALDH1A3 and ALDH2 of mouse, rat and human origin by Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Molecular Weight of ALDH1/2: 53 kDa.

Positive Controls: mouse liver extract: sc-2256, Hep G2 cell lysate: sc-2227 or A549 cell lysate: sc-2413.


STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.


RESEARCH USE

For research use only, not for use in diagnostic procedures.

DATA



ALDH1/2 (H-8): sc-166362. Near-infrared western blot analysis of ALDH1/2 expression in Hep G2 (A), A549 (B) and Caki-1 (C) whole cell lysates and human skeletal muscle (D), mouse liver (E) and human brain (F) tissue extracts. Blocked with UltraCruz® Blocking Reagent: sc-516214. Detection reagent used: m-IgGκ BP-CFL 680: sc-516180.



ALDH1/2 (H-8): sc-166362. Immunofluorescence staining of methanol-fixed HeLa cells showing cytoplasmic localization (A). Immunoperoxidase staining of formalin fixed, paraffin-embedded human gall bladder tissue showing cytoplasmic staining of glandular cells (B).

SELECT PRODUCT CITATIONS

- Xie, M.Q., et al. 2011. Modulation of immune tolerance with a Chinese traditional prescription inhibits allergic rhinitis in mice. *N. Am. J. Med. Sci.* 3: 503-507.
- Kumar, V., et al. 2017. Design, synthesis and biological evaluation of novel hedgehog inhibitors for treating pancreatic cancer. *Sci. Rep.* 7: 1665.
- Shishido, A., et al. 2018. Mesothelial cells facilitate cancer stem-like properties in spheroids of ovarian cancer cells. *Oncol. Rep.* 40: 2105-2114.
- Carvalho, M.J., et al. 2019. Endometrial cancer spheres show cancer stem cells phenotype and preference for oxidative metabolism. *Pathol. Oncol. Res.* 25: 1163-1174.
- Verma, S., et al. 2020. Androgen deprivation induces transcriptional reprogramming in prostate cancer cells to develop stem cell-like characteristics. *Int. J. Mol. Sci.* 21: 9568.
- Lee, H., et al. 2021. Repositioning trimebutine maleate as a cancer treatment targeting ovarian cancer stem cells. *Cells* 10: 918.
- Chu, T.H., et al. 2022. Leukocyte cell-derived chemotaxin 2 regulates epithelial-mesenchymal transition and cancer stemness in hepatocellular carcinoma. *J. Biol. Chem.* 298: 102442.
- Xie, G., et al. 2023. Recombinant immunotoxin induces tumor intrinsic STING signaling against head and neck squamous cell carcinoma. *Sci. Rep.* 13: 18476.
- Serambeque, B., et al. 2024. Influence of aldehyde dehydrogenase inhibition on stemness of endometrial cancer stem cells. *Cancers* 16: 2031.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.